Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-532-9 | CAS number: 142-29-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restriction.
Data source
Reference
- Reference Type:
- publication
- Title:
- Acute, Subacute and Subchronic Inhalation Toxicity of Cyclopentene
- Author:
- Kimmerle G., Thyssen J.
- Year:
- 1 975
- Bibliographic source:
- Int. Arch. Arbeitsmed. 34, 177-184
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- 4 groups of rats (10/sex/dose) were exposed to cyclopentene for 12 weeks.
Laboratory examinations of blood and urine were carried out. At the end of the exposure period all animals were sacrificed and the internal organs were macroscopically and histologically examined. - GLP compliance:
- not specified
Test material
- Reference substance name:
- Cyclopentene
- EC Number:
- 205-532-9
- EC Name:
- Cyclopentene
- Cas Number:
- 142-29-0
- Molecular formula:
- C5H8
- IUPAC Name:
- cyclopentene
- Details on test material:
- Analytical purity: 99.8 % (technical)
Constituent 1
- Specific details on test material used for the study:
- Appearance: pale yellow liquid
Qualities: specific gravity=0.772/20°C, slightly water-soluble, readily soluble in alcohols, hydrocarbons and chlorinated hydrocarbons
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Weight at study initiation: 140-150 g
- Housing: housed in groups of 5 in cages
- Diet (e.g. ad libitum): ad libitum (Altromin standard diet)
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20°C +/- 2°C
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- not specified
- Remarks:
- presumably whole body application
- Vehicle:
- not specified
- Details on inhalation exposure:
- - Subchronic study (12 weeks) - 4 groups of rats were exposed to concentrations of 0, 112, 317 or 1139 ppm.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - The effective cyclopentene concentration in the air was determined usign gas chromatography.
- A measured volume (1 1/min) was passed through three connected bottles in a series, each charged with 30 mL carbon tetrachloride over a period of 40 minutes.
- The carbon tetrachloride solutions were combined in a 100 mL volumetric flask and the content of cylopentene was determined. - Duration of treatment / exposure:
- 12 weeks
- Frequency of treatment:
- 6 hours/day for 5 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/L air
- Remarks:
- control
- Dose / conc.:
- 0.3 mg/L air
- Dose / conc.:
- 0.9 mg/L air
- Dose / conc.:
- 3.2 mg/L air
- No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- Post-exposure period: no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
HAEMATOLOGY: Yes
- Time schedule for collection of blood: one day before the end of the inhaltation test
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: one day before the end of the inhalation test
- How many animals: all
- Parameters checked: SGPT, SGOT, AP, bilirubin, urea, creatinine, glucose
URINALYSIS: Yes
- Time schedule for collection of urine: one day before the end of the inhalation test
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
heart, lungs, liver, spleen, kidneys, adrenals, thyroid, thymus and gonads
HISTOPATHOLOGY: Yes
heart, lungs, liver, spleen, kidneys, adrenals, thyroid, thymus and gonads ,prostata, lymph nodes, brain, eyes aorta, thigh-muscle and sternal bone - Statistics:
- Not specified
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No noticeable changes in appearance.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No noticeable changes in body weight.
(Body weight gain (in g) at 12 weeks: males - 106 (0.3 mg/ml), 93 (0.9 mg/ml), 93 (3.2 mg/ml) vs. 97 in the control group; females - 26 (0.3 mg/ml), 27 (0.9 mg/ml), 23 (3.2 mg/ml) vs. 25 in the control group) - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Haemotological values, serum-enzyme activities (SGOT, SGPT, P .P), urea, bilirubin, creatinine and glucose were within the physiological range.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No significant change in the composition of the urine.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- No noticeable changes in behaviour.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- None of the mean values of absolute or relative organ weights showed signfiicant differences among groups.
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No histopathological changes were observed that could have been attributed ot the inhalation of cyclopentene.
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 3.2 other: mg/l
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Results of haemotological examinations
concentrationmg/l | haemoglobing/100ml | RBC10^6/mm³ | Thrombocytes 10^3/mm³ | PVC % | Leucocytes | |||||
Total 10^3/mm³ | Neutro-phils % | Baso-phils% | Eosino-phils% | Lympho-cytes% | Mono-cytes% | |||||
Males | ||||||||||
0 | 14.6 | 8.43 | 995 | 49 | 7.6 | 17 | 1 | 0 | 8 | 0 |
0.3 | 14.4 | 8.45 | 1016 | 48 | 8.2 | 14 | 2 | 0 | 84 | 0 |
0.9 | 14.9 | 8.30 | 1003 | 50 | 5.8 | 18 | 1 | 0 | 81 | 0 |
3.2 | 14.4 | 34 | 980 | 48 | 79 | 16 | 1 | 0 | 83 | 0 |
Females | ||||||||||
0 | 14.0 | 7.78 | 1063 | 60 | 5.5 | 17 | 1 | 0 | 82 | 0 |
0.3 | 14.3 | 7.93 | 1095 | 61 | 5.1 | 16 | 2 | 0 | 82 | 0 |
0.9 | 14.1 | 8.02 | 1066 | 58 | 5.8 | 15 | 2 | 0 | 83 | 0 |
3.2 | 15.0 | 8.51 | 1118 | 58 | 6.1 | 19 | 1 | 0 | 80 | 0 |
means of groups of 10 rats
Results of clinical chemistry examinations
concentrationmg/l | SGOT mU/ml | SGPTmU/ml | APmU/ml | Ureamg/100ml | Creatinine mg/100 ml | Glucose mg/100 ml | Bilirubin mg/100 ml | |||
Males | ||||||||||
0 | 30.7 | 18.1 | 22.6 | 55.0 | 0.88 | 86.5 | 0.18 | |||
0.3 | 33.6 | 21.1 | 239 | 56.1 | 0.95 | 86.6 | 0.10 | |||
0.9 | 28.5 | 17.0 | 212 | 58.1 | 0.85 | 85.0 | 0.10 | |||
3.2 | 28.1 | 18.5 | 218 | 51.5 | 0.90 | 89.6 | 0.14 | |||
Females | ||||||||||
0 | 33.8 | 15.8 | 156 | 51.9 | 0.92 | 87.1 | 0.15 | |||
0.3 | 33.6 | 15.5 | 146 | 52.1 | 0.93 | 88.2 | 0.12 | |||
0.9 | 33.0 | 15.9 | 149 | 48.2 | 0.94 | 85.2 | 0.16 | |||
3.2 | 33.7 | 15.6 | 153 | 48.9 | 0.90 | 89.2 | 0.17 | |||
means of groups of 10 rats
Absolute and relative organ weights
Sex andconcentration (mg/l) | Organ weights | Terminal body weight | |||||||||
Thyroid | Thymus | Heart | Lung | Liver | Spleen | Kidneys | Adrenals | Gonads | |||
Absolut organ weight (mg) | |||||||||||
Males | |||||||||||
0 | 10.1 | 140 | 718 | 1027 | 7565 | 393 | 1733 | 30.0 | 2886 | 252 | |
0.3 | 10.2 | 151 | 723 | 1051 | 8097 | 388 | 1810 | 29.6 | 2821 | 261 | |
0.9 | 10.7 | 145 | 705 | 1046 | 7128 | 386 | 1659 | 27.8 | 2986 | 213 | |
3.2 | 10.7 | 155 | 721 | 1026 | 7630 | 382 | 1794 | 30.1 | 2869 | 244 | |
Females | |||||||||||
0 | 9.0 | 133 | 518 | 847 | 4974 | 292 | 1407 | 37.7 | 42.9 | 167 | |
0.3 | 9.1 | 150 | 535 | 881 | 4907 | 305 | 1418 | 35.8 | 44.5 | 168 | |
0.9 | 9.3 | 151 | 542 | 831 | 5105 | 290 | 1407 | 36.3 | 42.9 | 169 | |
3.2 | 9.4 | 142 | 515 | 851 | 4886 | 291 | 1386 | 36.4 | 41.0 | 701 | |
Relative organ weight (mg/100 g bw) | |||||||||||
Males | |||||||||||
0 | 4.0 | 55 | 285 | 409 | 3003 | 157 | 689 | 11.9 | 1167 | ||
0.3 | 3.9 | 58 | 278 | 403 | 3095 | 149 | 693 | 11.3 | 1061 | ||
0.9 | 4.3 | 58 | 284 | 423 | 2970 | 155 | 666 | 11.2 | 1205 | ||
3.2 | 4.3 | 63 | 296 | 422 | 3121 | 157 | 717 | 12.3 | 1181 | ||
Females | |||||||||||
0 | 5.4 | 80 | 310 | 488 | 2970 | 175 | 857 | 22.6 | 25.7 | ||
0.3 | 5.4 | 89 | 319 | 527 | 2925 | 182 | 841 | 21.3 | 26.5 | ||
0.9 | 5.5 | 89 | 321 | 493 | 3027 | 172 | 835 | 21.5 | 25.4 | ||
3.2 | 5.5 | 88 | 320 | 530 | 2981 | 180 | 832 | 22.7 | 25.8 |
Applicant's summary and conclusion
- Conclusions:
- This study investigated the repeated dose toxicity of the test substance, cyclopentene, when administed to rats at concentrations of up to 1120 ppm for 12 weeks. The NOAEL was determined to be > 3.2 mg/L in both male and female Wistar rats.
- Executive summary:
This study investigated the repeated dose toxicity of the test substance, cyclopentene, when administed to rats at concentrations of up to 1120 ppm for 12 weeks. The NOAEL and LOAEL weree determined to be > 3.2 mg/L in both male and female Wistar rats.
The 23 -week exposure of cyclopentene caused no noticeable changes in behvaiour, appearance or body weight. All parameters measured within the haemotological tests were within the physiological range and there were no changes to the composition of urine.
The NOAEL was both determined to be > 3.2 mg/L in both male and female Wistar II rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.